Despite the demonstrated importance of T cell metabolism in antitumor immune response in preclinical models, relatively few clinical trials have been conducted to investigate metabolic interventions in improving cancer immunotherapies aside from targeting IDO metabolism. Here, IDO1 is linked to cancer.